Sign in
Active, not recruitingNo phase

Assessment of a Chronically Implanted Parasternally Delivered EV-ICD Lead (ASCEND EV) Study

Key facts

Who runs it
AtaCor Medical, Inc.
Where
Croatia, New Zealand, and Paraguay3 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
19 people enrolled
Started
25 Feb 2025
Expected to end
31 Dec 2028
Type of study
Interventional
Treatments tested
  • Atala™ lead
Record updated
4 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • At least 18 years old
  • Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines

Who cannot take part

  • Participation in any concurrent clinical study without prior written approval from the Sponsor
  • Subjects on anticoagulation therapy that cannot be temporarily discontinued for the procedure
  • Implanted with or planned implantation of any device which delivers current in the body, that may interfere with therapy delivery, including, but not limited to a pacemaker, or neurostimulator
  • Prior sternotomy of any type, including but not limited to median, mini or clamshell
  • Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium
  • Inotropic therapy in past 180 days
  • Any known conditions which may complicate the AtaCor EV-ICD Lead System implant procedure or prevent the subject from completing protocol testing through the 3-month follow-up visit
  • Allergies to any device materials listed in the Instructions for Use (IFU)
  • Known history of lung disease with FEV1 < 1.0 Liter; Device Related:
  • Structural abnormalities of the heart that may increase risk of the study procedure or an obstructed/restricted pathway into the mediastinum
  • Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis) and associated with displacement of the heart or lungs or impeded mediastinal access
  • History of thoracic radiation therapy, pneumothorax, pneumomediastinum or other medical treatments/conditions which may complicate the AtaCor EV-ICD Lead System implant procedure
  • Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax
  • Surgically corrected congenital heart disease (not including catheter-based procedures); Cardiac Related:
  • Subjects who require permanent bradycardia pacing or cardiac resynchronization therapy
  • Known history of pericardial disease, pericarditis or mediastinitis
  • Patients with a medical condition that precludes them from undergoing defibrillation testing:; Severe aortic stenosis; Current Intracardiac LA or LV thrombus; Severe proximal three-vessel or left main coronary artery disease without revascularization; Hemodynamic instability; Unstable angina; Recent stroke or transient ischemic attack (within the last 6 months); Known inadequate external defibrillation; LVEF < 20%; LVEDD >70 mm
  • Inability or unwillingness to provide informed consent to participate in the Study
  • Circumstances that may prevent data collection or completion of specified follow-up visits
  • Presence or planned use of medical devices that introduce current into the body (e.g., pacemaker, LVAD, neurostimulator, etc.)
  • Presence or planned use of a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads
  • Any known need for future MRI; Anatomy Related:
  • BMI ≥ 35 kg/m2
  • NYHA IV functional class in past 90 days

Where is this trial?

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The ASCEND EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of the study is to evaluate the Investigational Devices through at least 3-months of follow-up to inform the design of a subsequent pivotal clinical investigation.

Read full original descriptionShow less

The objectives of the study are to: 1) preliminarily validate safety and effectiveness of the Atala™ lead as a permanent ICD lead when used with a compatible ICD pulse generator, 2) evaluate suitability of clinical study testing methods and 3) inform statistically powered primary safety and effectiveness endpoints in a subsequent pivotal clinical investigation.

The group in the trial

  • AtaCor EV-ICD Lead SystemTreatment being tested

    Subjects implanted with the Atala™ lead

    Treatment: Atala™ lead

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
4 December 2025